Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Diagnosed Essential Tremor in the United States: An Administrative Claims-Based Study.

Tremor and other hyperkinetic movements (New York, N.Y.)·2025
Same author

Epidemiology and treatment patterns of essential tremor: a retrospective cohort analysis in Germany.

Frontiers in neurology·2025
Same author

Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Circadian eating patterns track from infancy to pre- and primary school-age, but are not prospectively associated with body composition in childhood - Results of the DONALD cohort study.

European journal of nutrition·2025
Same author

Burden of tremor in Parkinson's disease: A survey study.

Journal of Parkinson's disease·2025
Same author

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.

Clinical parkinsonism & related disorders·2024
Same journal

Effects of physical exercise on neurofilament light chain in multiple sclerosis and other neurological disorders: A systematic review.

Multiple sclerosis and related disorders·2026
Same journal

Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same journal

Pregnancy among women with neuromyelitis optica spectrum disorder: An updated case series from Iran.

Multiple sclerosis and related disorders·2026
Same journal

Compartment-specific miRNA-gene expression patterns in relapsing-remitting multiple sclerosis: Clinical blood and cerebrospinal fluid validation.

Multiple sclerosis and related disorders·2026
Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026
Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.6K

Multiple sclerosis by phenotype in Germany.

Johanna Engelhard1, Denise M Oleske2, Sarah Schmitting3

  • 1IQVIA, Unterschweinstiege 2-14, 60549, Frankfurt, Germany.

Multiple Sclerosis and Related Disorders
|February 15, 2022
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) prevalence increased across all phenotypes (RRMS, PPMS, SPMS) with an aging population and shifting treatment patterns. Depression and cardiovascular conditions were common comorbidities, varying by MS type.

Keywords:
Drug utilizationEpidemiologyMultiple sclerosisPrimary progressive multiple sclerosisRelapsing-remitting multiple sclerosisSecondary progressive multiple sclerosis

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Sequential Photo-bleaching to Delineate Single Schwann Cells at the Neuromuscular Junction
11:12

Sequential Photo-bleaching to Delineate Single Schwann Cells at the Neuromuscular Junction

Published on: January 11, 2013

10.8K

Related Experiment Videos

Last Updated: Oct 3, 2025

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Sequential Photo-bleaching to Delineate Single Schwann Cells at the Neuromuscular Junction
11:12

Sequential Photo-bleaching to Delineate Single Schwann Cells at the Neuromuscular Junction

Published on: January 11, 2013

10.8K

Area of Science:

  • Neurology
  • Epidemiology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is classified into relapsing-remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS) phenotypes.
  • Existing studies often focus on RRMS or short-term drug utilization, lacking comprehensive population-based data on MS phenotypes over time.
  • Understanding MS phenotype burden, treatment, and comorbidities is crucial for effective healthcare strategies.

Purpose of the Study:

  • To compare MS phenotypes regarding changes in prevalence, drug utilization, and comorbidities over time.
  • To analyze population-based data from a German health insurance database (2010-2017).

Main Methods:

  • Retrospective, observational cohort study.
  • Utilized a German health insurance database from 2010 to 2017.
  • Included patients aged 18+ with specified MS phenotypes (ICD-10 coding).

Main Results:

  • MS prevalence increased for all phenotypes (RRMS +113%, PPMS +40%, SPMS +54%), with a generally aging patient population.
  • Disease-modifying drug use rose from 51% to 57%; interferon use declined, while PPMS and SPMS patients received more symptom management prescriptions.
  • Depression was the most prevalent comorbidity, highest in SPMS (44%). Cardiovascular conditions were highest in PPMS, and cognitive dysfunction highest in SPMS.

Conclusions:

  • Increasing MS patient numbers, an aging demographic, and phenotype-specific treatment and comorbidity patterns necessitate updated healthcare strategies.
  • These findings offer new insights into the disease burden and inform optimized care for diverse MS patient populations.
  • Consideration of these evolving trends is essential for developing effective MS management and healthcare policies.